2020.03.30
I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics for Commercialization Rights of CD73 Antibody, TJD5, for Immuno-Oncology
- Kalbe Genexine Biologics (“KG Bio”) will receive right of first negotiation for an exclusive license to potentially commercialize I-Mab’s TJD5, in Southeast Asia and other territories - Partnership to include right of first negotiation on an additional I-Mab-discovered product candidate to be agr...